Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of a 6-valent OspA-based Lyme disease vaccine in participants ≥5 years of age
2021-005427-20Phase 3Active
- Sponsor
- Pfizer
- Start
- Mar 2022
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in Lyme borreliosis comparing PF-07307405 vaccine arm with Placebo arm (2 arms). Primary endpoints: Primary efficacy, Safety and tolerability and 2 more. Started Mar 2022; status: active.
02
Drugs
VLA15
03
Conditions
Lyme borreliosis
Beyond the preview
Go deeper on 2021-005427-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005427-20.